2 Tower Place
South San Francisco
11 articles with ArsenalBio
ArsenalBio Announces First Patient Dosed in Phase 1 Clinical Trial of AB-1015 in Development as a Treatment for Ovarian Cancer
Arsenal Biosciences, Inc. today announced that the first patient has been dosed with AB-1015 in a Phase 1, first-in-human clinical trial for patients with ovarian cancer that is resistant to platinum-based regimens.
Genentech and privately-held Arsenal Biosciences forged a multi-year collaboration to identify critical success circuits in T cell-based therapies for solid tumors.
Biopharma Executive Perspectives on 2022
1/10/2022BioSpace sat down with 12 executives who shared their thoughts on the coming year and decade.
ArsenalBio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
Arsenal Biosciences, Inc., a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, today announced that members of its senior management team are scheduled to participate in the 40th Annual J.P. Morgan Healthcare Conference being held virtually on Monday, January 10, 2022.
ArsenalBio to Participate in Upcoming Investor Conferences
ArsenalBio today announced that Company leadership will participate in two upcoming virtual investor conferences: Piper Sandler 33rd Annual Virtual Healthcare Conference Format: On-Demand Presentation Date: November 29 – December 2, 2021.
ArsenalBio Announces Participation in Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
ArsenalBio today announced that it will present pre-clinical data from AB-X, the company’s integrated circuit T cell therapy program for the treatment of ovarian cancer (OC), at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting taking place November 10-14, 2021
BioSpace Movers & Shakers, July 23
7/23/2021Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
ArsenalBio Announces Appointment of John Schroer as Chief Financial Officer and Tim Sirichoke as Chief Technical Operations Officer
-- Follows recent appointments of Barbara Kosacz and Matthew Fust to ArsenalBio’s Board of Directors and Ken Drazan as Chairman of the Board -- -- Expansion of leadership will support programmable cell therapy pioneer’s continued pipeline, business and operations scale-up --
ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol Myers Squibb to Advance Next-Generation T cell Therapies for Solid Tumors
-- Partnership combines ArsenalBio’s programmable cell therapy approach with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development -- -- ArsenalBio employs a suite of proprietary technologies to encode synthetic biological instructions to overcome solid tumors’ complex defense systems --
ArsenalBio has entered into a multi-year discovery partnership with Bristol Myers Squibb to develop next-generation T cell therapies for solid tumors.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.